Vitespen

Drug Profile

Vitespen

Alternative Names: Cancer vaccine heat shock protein peptide complex-96 - Agenus; Cancer vaccine HSPPC-96; G-100; G-200; Heat shock protein peptide complex 96 cancer vaccine - Agenus; Heat-shock protein-based vaccine; HSPPC-96; NP-150; Oncophage; Prophage series G-100 vaccine; Prophage series G-200 vaccine; Prophage™ heat shock protein-based autologous vaccine

Latest Information Update: 07 Mar 2016

Price : $50

At a glance

  • Originator Fordham University; Mount Sinai School of Medicine
  • Developer Agenus; University of Texas Health Science Center at Houston
  • Class Antineoplastics; Cancer vaccines; Heat shock proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma; Glioma; Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Malignant melanoma; Renal cell carcinoma
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II Glioma; Malignant melanoma
  • Preclinical Brain cancer
  • No development reported Colorectal cancer; Gastric cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer
  • Discontinued Chronic myeloid leukaemia; Leukaemia; Sarcoma

Most Recent Events

  • 03 Mar 2016 Agenus plans a clinical trial for Glioblastoma (Newly diagnosed)
  • 08 Feb 2016 The University of Texas Health Science Center and Agenus withdraw a phase I/II trial for Malignant melanoma (Combination therapy, Late-stage disease) in USA (NCT02452281)
  • 04 Jun 2015 Vitespen is still in phase II trials for Glioma (Recurrent & Newly diagnosed, Combination therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top